Ralph-Edwards Anthony, Vanderlaan Rachel D, Bajona Pietro
Division of Cardiovascular Surgery, Toronto General Hospital, University of Toronto, Toronto, ON, Canada.
Department of Cardiovascular and Thoracic Surgery, University of Texas Southwestern Medical Center, Dallas, TX, USA.
Ann Cardiothorac Surg. 2017 Jul;6(4):410-415. doi: 10.21037/acs.2017.07.08.
Hypertrophic cardiomyopathy (HCM) is the most common congenital cardiac disease, affecting up to 1 in 200 individuals. When it causes left ventricular outflow tract (LVOT) obstruction, treatment is indicated to reduce symptoms and the risk of sudden cardiac death. Pharmacologic therapy is the first line treatment, however if it fails, surgical myectomy or percutaneous ablation of the hypertrophic myocardium are the standard therapies to eliminate subaortic obstruction. Both surgical myectomy and percutaneous ablation have been demonstrated as safe and effective treatments; however, myectomy is the gold standard with a significantly lower complication rate and more complete and longstanding reduction of LVOT obstruction.
肥厚型心肌病（HCM）是最常见的先天性心脏病，每200人中就有1人受其影响。当它导致左心室流出道（LVOT）梗阻时，就需要进行治疗以减轻症状并降低心源性猝死风险。药物治疗是一线治疗方法，然而，如果治疗失败，外科心肌切除术或经皮肥厚心肌消融术是消除主动脉瓣下梗阻的标准治疗方法。外科心肌切除术和经皮消融术均已被证明是安全有效的治疗方法；然而，心肌切除术是金标准，其并发症发生率显著更低，能更彻底、持久地减轻LVOT梗阻。
